12:00 AM
Aug 17, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Embeda regulatory update

King said FDA approved Embeda to manage moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda is an extended-release formulation of morphine, an opioid receptor agonist, which includes a sequestered pellet core of naltrexone. The label includes data from abuse deterrence...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >